Biocad

Biotechnology (biosimilars + biologics)

Privately held: no public share price · Russia

Assets

(8 total)
8Total Assets
0Approved
7Phase 3 / Filed
1Phase 1–2 / Early
8Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
AcellbiaNo recent activity
Phase 3
CD20Monoclonal antibody
Rheumatoid Arthritis
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis
Divozilimab(Ivlizi)
Phase 3
CD20Monoclonal antibody
Systemic Lupus ErythematosusMultiple SclerosisSystemic Sclerosis
Levilimab(Ilsira)
Phase 3
IL-6 receptorMonoclonal antibody
Rheumatoid ArthritisCOVID-19
Phase 3
IL-17Monoclonal antibody
Psoriatic ArthritisPsoriasis
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 1
BDCA2 (CLEC4C)Monoclonal antibody
Systemic Lupus Erythematosus

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
July 2028 (1)
TorutamigPhase 3Myeloma Multiple
Est. primary completion 2028-07 · NCT07742215 · CT.gov ↗
What to watch
December 2028 (1)
BCD-281Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)
Est. primary completion 2028-12 · NCT07321093 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.